StocksMedium•11 November 2026•
1 min read
MiNK Therapeutics Records First Product Revenue in Q3 2026 Results
Key Facts
1MiNK Therapeutics realized its first pre-commercial product revenue from agenT-797 during the third quarter of 2026.
2The company's cells were selected by an ARPA-H program to generate living medicines deliverable without a freezer.
MiNK Therapeutics realized its first pre-commercial product revenue from agenT-797 during the third quarter of 2026. GlobeNewswire reported that the company is transitioning from a purely clinical stage to generating initial revenue while advancing its clinical trials for acute respiratory distress syndrome (ARDS).
The company's cells were selected by an ARPA-H program to generate living medicines deliverable without a freezer, expanding its cell therapy platform. INKT closed at $10.01 on November 10, 2026, having reached a day high of $10.5 during the session.